Jonas Jegerborn 의 보수는 Generic Sweden 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	SEK 23m
Mar 31 2024	n/a	n/a	SEK 23m
Dec 31 2023	SEK 3m	n/a	SEK 23m
Sep 30 2023	n/a	n/a	SEK 24m
Jun 30 2023	n/a	n/a	SEK 23m
Mar 31 2023	n/a	n/a	SEK 21m
Dec 31 2022	SEK 3m	n/a	SEK 20m
Sep 30 2022	n/a	n/a	SEK 19m
Jun 30 2022	n/a	n/a	SEK 18m
Mar 31 2022	n/a	n/a	SEK 19m
Dec 31 2021	SEK 3m	n/a	SEK 18m
Sep 30 2021	n/a	n/a	SEK 17m
Jun 30 2021	n/a	n/a	SEK 15m
Mar 31 2021	n/a	n/a	SEK 13m
Dec 31 2020	SEK 3m	n/a	SEK 11m
Sep 30 2020	n/a	n/a	SEK 10m
Jun 30 2020	n/a	n/a	SEK 10m
Mar 31 2020	n/a	n/a	SEK 9m
Dec 31 2019	SEK 2m	SEK 1m	SEK 9m

보상 대 시장: Jonas 의 총 보상 ($USD 283.81K )은 Swedish 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 279.51K ).

보상과 수익: Jonas 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Jonas Jegerborn (52 yo)

no data

테뉴어

SEK 2,888,000

보상

Mr. Jonas Jegerborn serves as the Chief Executive Officer and President at Generic Sweden AB.

리더십 팀

이름	위치	테뉴어	보상	소유권
Jonas Jegerborn	President & CEO	no data	SEK 2.89m	1.47% SEK 8.1m
Susanne Lundin	Chief Financial Officer	3.6yrs	데이터 없음	데이터 없음
Magnus Rasmusson	Chief Technology Officer	4.8yrs	데이터 없음	데이터 없음
Madelene Persson	Marketing Manager	5.7yrs	데이터 없음	데이터 없음

4.8yrs

평균 재임 기간

47yo

평균 연령

경험이 풍부한 관리: GENI 의 관리팀은 경험 ( 4.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Bengt-Arne Molin	Independent Director	4.3yrs	SEK 100.00k	0.055% SEK 300.8k
Hans Krantz	Chairman of the Board	14.8yrs	SEK 200.00k	21.82% SEK 119.9m
Stefan Widen	Independent Director	10.3yrs	SEK 100.00k	데이터 없음
Johanna Berlinde	Independent Director	1.3yrs	SEK 100.00k	데이터 없음
Erik Ivarsson	Director	2.3yrs	SEK 100.00k	0.11% SEK 625.8k

4.3yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: GENI 의 이사회는 경험(평균 재직 기간 4.1 년)으로 간주됩니다.

Generic Sweden 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

Owner & Member of the board recently sold kr3.5m worth of stock

Owner & Member of the board recently sold kr3.1m worth of stock

Owner & Member of the board recently sold kr1.4m worth of stock

Owner & Member of the board recently sold kr1.3m worth of stock

Should You Take Comfort From Insider Transactions At Generic Sweden AB (STO:GENI)?

Recent updates

Generic Sweden's (STO:GENI) Profits May Not Reveal Underlying Issues

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 24% undervalued after recent price drop

Now 23% undervalued after recent price drop

Now 20% undervalued

First quarter 2024 earnings: Revenues exceed analyst expectations

Now 23% undervalued

Upcoming dividend of kr1.50 per share

Now 23% undervalued after recent price drop

Some Confidence Is Lacking In Generic Sweden AB (STO:GENI) As Shares Slide 29%

Generic Sweden's (STO:GENI) Solid Earnings May Rest On Weak Foundations

Do Generic Sweden's (STO:GENI) Earnings Warrant Your Attention?

Full year 2023 earnings: EPS misses analyst expectations

Investor sentiment deteriorates as stock falls 16%

Now 25% undervalued

Should You Investigate Generic Sweden AB (STO:GENI) At kr60.20?

Investor sentiment improves as stock rises 16%

Now 22% undervalued

Third quarter 2023 earnings: Revenues exceed analyst expectations

Investor sentiment improves as stock rises 21%

Is Now The Time To Look At Buying Generic Sweden AB (STO:GENI)?

New major risk - Earnings quality

Investor sentiment improves as stock rises 17%

Should You Be Adding Generic Sweden (STO:GENI) To Your Watchlist Today?

Upcoming dividend of kr1.25 per share at 2.9% yield

Full year 2022 earnings: EPS exceeds analyst expectations

Investor sentiment improves as stock rises 21%

Full year 2022 earnings: EPS exceeds analyst expectations

Is Generic Sweden AB (STO:GENI) Potentially Undervalued?

Now 21% undervalued

Now 21% undervalued

Third quarter 2022 earnings: Revenues exceed analyst expectations

Investor sentiment improved over the past week

Second quarter 2022 earnings: Revenues miss analyst expectations

We Ran A Stock Scan For Earnings Growth And Generic Sweden (STO:GENI) Passed With Ease

Investor sentiment deteriorated over the past week

Now 23% undervalued after recent price drop

First quarter 2022 earnings: Revenues miss analyst expectations

Upcoming dividend of kr1.00 per share

A Look At The Intrinsic Value Of Generic Sweden AB (STO:GENI)

Less than half of directors are independent

Is It Time To Consider Buying Generic Sweden AB (STO:GENI)?

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Now 23% undervalued after recent price drop

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Is Now The Time To Put Generic Sweden (STO:GENI) On Your Watchlist?

Investor sentiment improved over the past week

Calculating The Fair Value Of Generic Sweden AB (STO:GENI)

Investor sentiment deteriorated over the past week

Owner & Member of the board recently sold kr3.5m worth of stock

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Owner & Member of the board recently sold kr3.1m worth of stock

Third quarter 2021 earnings released

With EPS Growth And More, Generic Sweden (STO:GENI) Is Interesting

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released

Investor sentiment improved over the past week

Here's Why I Think Generic Sweden (STO:GENI) Is An Interesting Stock

Owner & Member of the board recently sold kr1.4m worth of stock

Owner & Member of the board recently sold kr1.3m worth of stock

Investor sentiment improved over the past week

First quarter 2021 earnings released

Upcoming dividend of kr0.80 per share

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week